Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 4/20 | 0.41 |
| ▸ | NAAA | Q02083 | 2/20 | 0.37 |
| ▸ | DGKA | P23743 | 1/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10972586 | 0.95 | PRKCA (0.40) | PRKCANAAADGKA | |
| SCHEMBL798209 | 0.88 | GAA (0.41) | PRKCAMGAMGAASIMGAM2 | |
| SCHEMBL773587 | 0.88 | GAA (0.41) | PRKCAMGAMGAASIMGAM2 | |
| SCHEMBL14032871 | 0.81 | CYP1A2 (0.40) | MGAMGAASIMGAM2KMT2A | |
| SCHEMBL31252203 | 0.81 | PRKCA (0.41) | PRKCAMGAMGAASIMGAM2 | |
| SCHEMBL28122667 | 0.81 | CYP4F2 (0.40) | PRKCANAAA | |
| SCHEMBL798216 | 0.80 | CYP4F2 (0.44) | GAA | |
| SCHEMBL9013508 | 0.79 | DGKA (0.40) | PRKCANAAADGKA | |
| SCHEMBL882535 | 0.79 | KMT2A (0.37) | PRKCAMGAMGAASIMGAM2 | |
| SCHEMBL16877111 | 0.79 | GAA (0.43) | MGAMGAASIMGAM2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230107538-A1 | CYCLOALKYL-CONTAINING CARBOXYLIC ACIDS AND USES THEREOF | Liminal Biosciences Limited (GB) | 2023-04-06 | — | — | US | disclosed |
| US-20230107538-A1 | CYCLOALKYL-CONTAINING CARBOXYLIC ACIDS AND USES THEREOF | Liminal Biosciences Limited (GB) | 2023-04-06 | — | — | US | disclosed |
| EP-4076649-A1 | CYCLOALKYL-CONTAINING CARBOXYLIC ACIDS AND USES THEREOF | Liminal Biosciences Limited (GB) | 2022-10-26 | — | — | EP | disclosed |
| CN-114828958-A | Cycloalkyl-containing carboxylic acids and use thereof | 里米诺生物科学有限公司 | 2022-07-29 | — | — | CN | disclosed |
| WO-2021124272-A1 | CYCLOALKYL-CONTAINING CARBOXYLIC ACIDS AND USES THEREOF | Liminal Biosciences Limited (GB) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230107538-A1 | CYCLOALKYL-CONTAINING CARBOXYLIC ACIDS AND USES THEREOF | HCCS, CCL11, BCAT1 | PRKCA 2005/4885NAAA 1654/4885DGKA 2494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.